Global Antihyperlipidemic Drugs Market to Reach US$ 18.2 Billion by 2032, Impelled by Rising Prevalence of Hyperlipidemia

IMARC Group's latest report, titled "Antihyperlipidemic Drugs Market Report by Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Stores, Online Retailers), and Region 2024-2032," finds that the global antihyperlipidemic drugs market size reached US$ 12.6 Billion in 2023. Antihyperlipidemic drugs help in lowering blood lipid levels, including cholesterol. These medications are also known as hypolipidemic or lipid-lowering drugs in reference to their main physiological effects. They can be taken along with different medicines to lower cholesterol and reduce the risk of developing certain diseases. Some commonly available antihyperlipidemic drugs include cholesterol absorption inhibitors, fibric acid derivatives, statins, antihyperlipidemic combinations, bile acid sequestrants, and PCSK9 inhibitors. These drugs can prevent absorption, facilitate the elimination of more lipids in feces, and increase good cholesterol levels to lower bad cholesterol. At present, antihyperlipidemic drugs are available in different classes across the globe, which can be given depending on the patient’s underlying disease, cholesterol profile, and other factors. 

Global Antihyperlipidemic Drugs Market Trends:

The rising prevalence of hyperlipidemia due to the high consumption of fatty foods and nicotine addiction represents the primary factor driving the market growth. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is a leading cause of death among adults. In line with this, the escalating demand for antihyperlipidemic drugs to improve the low levels of high-density lipoprotein (HDL) cholesterol while reducing the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides are positively influencing the market growth. Additionally, antihyperlipidemic drugs are used to treat high cholesterol levels and various lipid disorders in children. Along with this, the rising product demand to reduce hospitalization rates and premature deaths due to the increase in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population has catalyzed market growth. Furthermore, several key players are developing, synthesizing, and evaluating a variety of new molecules for these drugs, thereby contributing to market growth. Other factors, including the rising prevalence of sedentary lifestyles, increasing incidences of cardiovascular disorders, surging approval of new and advanced drugs, and expanding geriatric population, are also anticipated to create a positive market outlook. Looking forward, IMARC Group expects the market value to reach US$ 18.2 Billion by 2032, expanding at a CAGR of 4.1% during 2024-2032.

Market Summary:

• Based on the drug class, the market has been divided into statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, PCSK9 inhibitors, combination, and others. 
• On the basis of the route of administration, the market has been bifurcated into oral and intravenous. 
• The market has been categorized based on the distribution channel into hospital pharmacies, retail stores, and online retailers.
• Region-wise, the market has been segregated into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others) and Middle East and Africa.
• The competitive landscape of the market has also been examined, with some of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi S.A.

Report Scope:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N A
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800